Arix Bioscience PLC
Andrew Smith is an accomplished executive leader with over 30 years’ international experience within the bio-pharma sector. He currently serves as Chief Financial Officer for Santhera Pharmaceuticals AG, a global specialty pharmaceutical company focused on developing medicines for rare diseases. Before joining Santhera he held the roles of CFO and COO Allecra Therapeutics GmbH and CFO at Sucampo Pharmaceuticals Inc. Together with previous senior financial and operations roles focusing on business improvement and transformation he has gained significant exposure to European and US markets working in public and private organizations with a focus on start-ups, spinoffs and growth and has been involved in a number of capital market transactions in excess of USD 700 million.
Andrew is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant. He studied business and accounting at Liverpool John Moores University and Durham University Business School.
Andrew joined the Arix Board in August 2022 and is Chair of the Audit Committee and a member of the Nomination Committee.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Arix Bioscience PLC
Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.